Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-10

Study Completion Date

2027-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV.

One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase).

Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

NCT00807443

HIV-1 HIV Infections

COMPLETED PHASE2

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

NCT00709397

HIV-1 Infection

TERMINATED

Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir

NCT04741100

HIV

WITHDRAWN

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

NCT05215704

HIV Infections HIV-1-infection HIV-2 Infection

RECRUITING

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

NCT00685191

HIV Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

20 ml of blood (5 tubes of 4 ml each) will be collected from 24 people living with HIV who are on ART. The inclusion criteria for this study are: being HIV-positive, having an undetectable viral load for more than 12 months, and having a history of very low T-CD4 counts (nadir \< 200 cells/mm³).

In the lab, investigators will isolate immune cells (PBMCs) from the blood using a special technique. These cells will then be placed in small wells and treated with LRAs for 18-20 hours. Investigators will measure the virus produced in the cell supernatant using two methods: q-RT-PCR for viral RNA and p24 ELISA for viral protein. The results will be analyzed using conventional statistical methods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Sampling

20 ml of blood (5 tubes of 4 ml) will be collected once.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 18 years or older
* HIV-positive
* On ART (antiretroviral therapy)
* HIV-1 RNA undetectable for more than 12 months
* Nadir CD4 count \< 200/µL

Exclusion Criteria

* Lack of antiretroviral treatment
* Immunosuppressive treatments
* History of cancer less than 5 years old
* Pregnant or breast-feeding women
* Persons protected by law (under guardianship or curators), persons under court protection
* Participating in another research project with an ongoing exclusion period
* Refusal to participate in research
* Subject not affiliated to a social security scheme, or not benefiting from such a scheme.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No